Chekir Chebib, Emi Yayoi, Arai Fujimi, Kikuchi Yukako, Sasaki Aiko, Matsuda Miwa, Shimizu Keiko, Tabuchi Kazuhiro, Kamada Yasuhiko, Hiramatsu Yuji, Nakatsuka Mikiya
Department of Obstetrics and Gynecology, Okayama University Hospital, Okayama, Japan.
J Obstet Gynaecol Res. 2012 Jun;38(6):932-40. doi: 10.1111/j.1447-0756.2011.01815.x. Epub 2012 Apr 9.
Male-to-female (MTF) transsexuals are treated with estrogen with and without progestin through a variety of routes. The aim of this study is to evaluate the arterial stiffness in MTF transsexuals undergoing hormonal treatment.
We evaluated the arterial stiffness in 156 MTF transsexuals (22 untreated and 129 treated with estrogen only or plus progestin) using a volume-plethysmographic apparatus equipped with a multi-element applanation tonometry sensor.
MTF transsexuals treated with parenteral estrogen were significantly older than untreated MTF transsexuals. Hematocrit, uric acid and activated partial thromboplastin time in treated MTF transsexuals were significantly lower than in untreated MTF transsexuals. The level of high-density lipoprotein cholesterol in MTF transsexuals treated with oral estrogen was significantly higher than in untreated MTF transsexuals or those treated with parenteral estrogen with and without progestin. The systolic blood pressure in MTF transsexuals treated with estrogen only is significantly lower than that in untreated MTF transsexuals. The brachial-ankle pulse wave velocity was significantly decreased in MTF transsexuals treated with estrogen compared to that in untreated MTF transsexuals or in those treated with estrogen plus progestin. The carotid augmentation index in MTF transsexuals treated with oral estrogen was significantly lower than that in MTF transsexuals treated with parenteral estrogen or oral estrogen plus progestin.
Estrogen treatment is likely to have some beneficial effects on lipid metabolism and vascular function in MTF transsexuals; however, progestin administered with estrogen may have adverse effects on arterial stiffness.
男变女（MTF）变性者通过多种途径接受雌激素治疗，部分联合孕激素。本研究旨在评估接受激素治疗的MTF变性者的动脉僵硬度。
我们使用配备多元素压平式眼压计传感器的体积描记仪评估了156例MTF变性者（22例未治疗，129例仅接受雌激素治疗或联合孕激素治疗）的动脉僵硬度。
接受胃肠外雌激素治疗的MTF变性者比未治疗的MTF变性者年龄显著更大。接受治疗的MTF变性者的血细胞比容、尿酸和活化部分凝血活酶时间显著低于未治疗的MTF变性者。接受口服雌激素治疗的MTF变性者的高密度脂蛋白胆固醇水平显著高于未治疗的MTF变性者或接受胃肠外雌激素治疗（无论是否联合孕激素）的MTF变性者。仅接受雌激素治疗的MTF变性者的收缩压显著低于未治疗的MTF变性者。与未治疗的MTF变性者或接受雌激素加孕激素治疗的MTF变性者相比，接受雌激素治疗的MTF变性者的臂踝脉搏波速度显著降低。接受口服雌激素治疗的MTF变性者的颈动脉增强指数显著低于接受胃肠外雌激素治疗或口服雌激素加孕激素治疗的MTF变性者。
雌激素治疗可能对MTF变性者的脂质代谢和血管功能有一些有益影响；然而，与雌激素联合使用的孕激素可能对动脉僵硬度有不良影响。
